Abstracts

• Thalassemia: the continued challenge

  DG Nathan

  https://doi.org/10.4081/hmr.v1i8.272

  176

  PDF: 800

  • PDF

• Deferasirox (ICL670): from bench to bedside

  DG Alberti

  https://doi.org/10.4081/hmr.v1i8.273

  255

  PDF: 698

  • PDF

• ICL670: clinical outcome

  MD Cappellini

  https://doi.org/10.4081/hmr.v1i8.274

  176

  PDF: 336

  • PDF

• Treatment of aggressive lymphoma

  Christer Gisselbrecht

  https://doi.org/10.4081/hmr.v1i8.275

  161

  PDF: 198

  • PDF

• Gemtuzumab ozogamicin

  S.L. Amadori

  https://doi.org/10.4081/hmr.v1i8.276

  169

  PDF: 178

  • PDF

• Imatinib – an overview

  MVN Deininger

  https://doi.org/10.4081/hmr.v1i8.277

  473

  PDF: 4432

  • PDF

• SKI-606 and beyond

  DH Boschelli, F Boschelli, B Wu, F Ye, Y Wang, JM Golas, T Young, J Lucas

  https://doi.org/10.4081/hmr.v1i8.278

  220

  PDF: 473

  • PDF

• Follicular lymphomas

  P Solal-Celigny

  https://doi.org/10.4081/hmr.v1i8.279

  151

  PDF: 252

  • PDF

• Anti-CD80 monoclonal antibody: galiximab

  MS Czuczman

  https://doi.org/10.4081/hmr.v1i8.280

  197

  PDF: 1260

  • PDF

• CD30: a suitable target for immunotherapy?

  Paola Borchmann

  https://doi.org/10.4081/hmr.v1i8.281

  176

  PDF: 499

  • PDF

• Palifermin (Kepivance™) in the treatment of mucositis

  Christer Emmanouilides

  https://doi.org/10.4081/hmr.v1i8.282

  193

  PDF: 381

  • PDF

• Combinations of biological agents in non-Hodgkin’s lymphomas

  BD Cheson

  https://doi.org/10.4081/hmr.v1i8.283

  159

  PDF: 281

  • PDF

• Chronic lymphocytic leukemia

  MS Gentile, A Guarini, FR Mauro, R Foà

  https://doi.org/10.4081/hmr.v1i8.284

  204

  PDF: 407

  • PDF

• Bcr-abl peptides for chronic myeloid leukemia

  MS Bocchia, M Ippoliti, MT Pirrotta, E Abruzzese, MM Trawinska, F Forconi

  https://doi.org/10.4081/hmr.v1i8.285

  209

  PDF: 458

  • PDF

• Tumor idyotipe as target antigen for multiple myeloma

  A.B. Curti

  https://doi.org/10.4081/hmr.v1i8.286

  159

  PDF: 302

  • PDF

• Augmenting anti-tumor efficacy of adoptive immunotherapy with marrow infiltrating lymphocytes

  I Borrello

  https://doi.org/10.4081/hmr.v1i8.287

  150

  PDF: 206

  • PDF

• Bortezomib therapy for refractory/relapsed multiple myeloma

  M Cavo

  https://doi.org/10.4081/hmr.v1i8.288

  192

  PDF: 191

  • PDF

• Ubiquitin-proteasome system is a sensitive target in Ph+ leukemia

  G Martinelli, D Cilloni, G Rosti, P Piccaluga, M Rondoni, C Bosi, S Paolini, F Pane, M Amabile, G Nadali, B Izzo

  https://doi.org/10.4081/hmr.v1i8.289

  222

  PDF: 279

  • PDF

• Bortezomib in lymphoma

  A Goy

  https://doi.org/10.4081/hmr.v1i8.290

  161

  PDF: 163

  • PDF

• Beyond bortezomib alone: combination therapy and new strategies in targeting the proteasome

  PG Richardson

  https://doi.org/10.4081/hmr.v1i8.291

  185

  PDF: 265

  Untitled: 0

  • PDF

• Thalidomide analogs

  P Tosi, E Zamagni, D Cangini, P Tacchetti, G Perrone, M Ceccolini, M Cavo

  https://doi.org/10.4081/hmr.v1i8.292

  211

  PDF: 532

  • PDF

• Tipifarnib in hematologic malignancies

  J-L Harousseau

  https://doi.org/10.4081/hmr.v1i8.293

  167

  PDF: 327

  • PDF

• Direct and indirect antitumor activity of zoledronic acid

  M Massaia, S Mariani, F Pantaleoni, M Muraro, S Peola, SY Hwang, B Castella, G Matta

  https://doi.org/10.4081/hmr.v1i8.294

  240

  PDF: 319

  • PDF

• MLN518 – an overview

  MVN Deininger

  https://doi.org/10.4081/hmr.v1i8.295

  295

  PDF: 326

  • PDF

• Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies

  K Bhalla

  https://doi.org/10.4081/hmr.v1i8.296

  228

  PDF: 363

  • PDF

• Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies

  OA O’Connor

  https://doi.org/10.4081/hmr.v1i8.297

  383

  PDF: 509

  • PDF

• Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma

  SM Ansell, SM Geyer, PJ Kurtin, KM Rowland, PJ Flynn, RF Morton

  https://doi.org/10.4081/hmr.v1i8.298

  239

  PDF: 431

  • PDF

• Gemcitabine: from solid tumor to hematology?

  PL Zinzani, M Tani, V Stefoni, E Marchi, M Fina, L Alinari

  https://doi.org/10.4081/hmr.v1i8.299

  177

  PDF: 444

  • PDF

• The developing role of clofarabine in acute leukemias

  S Faderl

  https://doi.org/10.4081/hmr.v1i8.300

  186

  PDF: 276

  • PDF

• Oral fludarabine

  GEG Verhoef

  https://doi.org/10.4081/hmr.v1i8.301

  148

  PDF: 425

  • PDF

• Oxaliplatin in lymphoma

  C Haioun

  https://doi.org/10.4081/hmr.v1i8.302

  162

  PDF: 866

  • PDF

• Lymphomatous meningitis

  C Hatton

  https://doi.org/10.4081/hmr.v1i8.303

  417

  PDF: 2863

  • PDF